Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions
Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions

NCT06257420

Enrolling By InvitationN/A

Sponsor: Simmaron Research Inc.

Conditions: Myalgic Encephalomyelitis, Long-COVID

Interventions: Rapamycin

Countries: United States

The goal of this observational study is to assess the clinical response and the effect of autophagy function in patients before, during and throughout oral low dose sirolimus (rapamycin) therapy. The main questions this study aims to answer are: * Does rapamycin reduce the overall symptom burden in this patient population and does it improve the quality of life? * Does rapamycin change mTOR driven autophagy deficits observed in a subset of patients? Participants will be asked to complete a series of questionnaires and quality of life instruments before starting rapamycin therapy prescribed by their physician and throughout their course of treatment. Study blood samples will be collected before starting therapy and throughout the course of treatment to assess serological markers of autophagy function.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Diagnosis of ME/CFS that meets the Institute of Medicine (IOM) criteria
* Diagnosis of Long-COVID (PASC clinical criteria)

Exclusion Criteria:

* No diagnosis of ME/CFS or Long-COVID
Locations (5)
  • Palo Alto, California, United States
  • Rochester, Minnesota, United States
  • Incline Village, Nevada, United States
  • Salt Lake City, Utah, United States
  • Seattle, Washington, United States